866-997-4948(US-Canada Toll Free)

Eosinophil Peroxidase (EPO or EPX or EC 1.11.1.7) - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Dec 2016

Category :

Pharmaceutical

No. of Pages : 22 Pages

Eosinophil Peroxidase (EPO or EPX or EC 1.11.1.7) - Pipeline Review, H2 2016

Summary

Global Markets Directs, Eosinophil Peroxidase (EPO or EPX or EC 1.11.1.7) - Pipeline Review, H2 2016, provides in depth analysis on Eosinophil Peroxidase (EPO or EPX or EC 1.11.1.7) targeted pipeline therapeutics.

The report provides comprehensive information on the Eosinophil Peroxidase (EPO or EPX or EC 1.11.1.7), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Eosinophil Peroxidase (EPO or EPX or EC 1.11.1.7) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Eosinophil Peroxidase (EPO or EPX or EC 1.11.1.7)
- The report reviews Eosinophil Peroxidase (EPO or EPX or EC 1.11.1.7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Eosinophil Peroxidase (EPO or EPX or EC 1.11.1.7) targeted therapeutics and enlists all their major and minor projects
- The report assesses Eosinophil Peroxidase (EPO or EPX or EC 1.11.1.7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Eosinophil Peroxidase (EPO or EPX or EC 1.11.1.7) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Eosinophil Peroxidase (EPO or EPX or EC 1.11.1.7)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Eosinophil Peroxidase (EPO or EPX or EC 1.11.1.7) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Introduction 4
Global Markets Direct Report Coverage 4
Eosinophil Peroxidase (EPO or EPX or EC 1.11.1.7) Overview 5
Therapeutics Development 6
Eosinophil Peroxidase (EPO or EPX or EC 1.11.1.7) - Products under Development by Stage of Development 6
Eosinophil Peroxidase (EPO or EPX or EC 1.11.1.7) - Products under Development by Therapy Area 7
Eosinophil Peroxidase (EPO or EPX or EC 1.11.1.7) - Products under Development by Indication 8
Eosinophil Peroxidase (EPO or EPX or EC 1.11.1.7) - Pipeline Products Glance 9
Early Stage Products 9
Eosinophil Peroxidase (EPO or EPX or EC 1.11.1.7) - Products under Development by Companies 10
Eosinophil Peroxidase (EPO or EPX or EC 1.11.1.7) - Therapeutics Assessment 12
Assessment by Monotherapy/Combination Products 12
Assessment by Mechanism of Action 13
Assessment by Molecule Type 14
Eosinophil Peroxidase (EPO or EPX or EC 1.11.1.7) - Companies Involved in Therapeutics Development 15
INOXIA Lifesciences GmbH 15
Eosinophil Peroxidase (EPO or EPX or EC 1.11.1.7) - Drug Profiles 16
AW/EPO-002 - Drug Profile 16
Product Description 16
Mechanism Of Action 16
R&D Progress 16
AW/EPO-003 - Drug Profile 17
Product Description 17
Mechanism Of Action 17
R&D Progress 17
AW/EPOPD-01 - Drug Profile 18
Product Description 18
Mechanism Of Action 18
R&D Progress 18
AW/EPOPD-02 - Drug Profile 19
Product Description 19
Mechanism Of Action 19
R&D Progress 19
AW/EPOPD-06 - Drug Profile 20
Product Description 20
Mechanism Of Action 20
R&D Progress 20
Appendix 21
Methodology 21
Coverage 21
Secondary Research 21
Primary Research 21
Expert Panel Validation 21
Contact Us 21
Disclaimer 22

List of Tables
Number of Products under Development for, H2 2016 6
Number of Products under Development by Therapy Area, H2 2016 7
Number of Products under Development by Indication, H2 2016 8
Comparative Analysis by Early Stage Products, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Products under Development by Companies, H2 2016 11
Assessment by Monotherapy/Combination Products, H2 2016 12
Number of Products by Stage and Mechanism of Action, H2 2016 13
Number of Products by Stage and Molecule Type, H2 2016 14
Pipeline by INOXIA Lifesciences GmbH, H2 2016 15

List of Figures
Number of Products under Development by Therapy Area, H2 2016 7
Number of Products under Development by Top 10 Indication, H2 2016 8

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *